Clinical Trial

A Study of MHB042C in Patients With Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a first-in-human, open-label, multicenter Phase I/II study of MHB042C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MHB042C monotherapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-17.
Trial Details
NCT Number NCT07192107
Lead Sponsor Minghui Pharmaceutical (Hangzhou) Ltd
Conditions Advanced Malignant Solid Tumor
Enrollment 200 participants
Start Date 2025-11-27
Primary Completion 2029-10 (estimated)
Study Completion 2029-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-09